TG Therapeutics Inc
TGTX
查看详细走势图
28.860USD
+1.100+3.96%
收盘 02/06, 16:00（美东）报价延迟15分钟
4.48B总市值
9.43市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.96%
5天
-1.94%
1月
-5.38%
6月
+8.05%
今年开始到现在
-3.19%
1年
-12.78%
查看详细走势图
TradingKey TG Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
TG Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名81/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价44.17。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
TG Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
TG Therapeutics Inc亮点
亮点风险
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
业绩高增长
公司营业收入稳步增长，连续3年增长11713.43%
估值合理
公司最新PE估值9.43，处于3年历史合理位
机构减仓
最新机构持股103.02M股，环比减少14.69%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值35.00
活跃度增加
近期活跃度增加，过去20天平均换手率-0.19
分析师目标
根据
9
位分析师
买入
评级
44.167
目标均价
+53.04%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TG Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TG Therapeutics Inc简介
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
公司代码TGTX
公司TG Therapeutics Inc
CEOWeiss (Michael S)
网址https://www.tgtherapeutics.com/
相关品种
